# Hepatocellular Carcinoma (HCC)_Torisel_

> **NCT01251458** · PHASE1,PHASE2 · COMPLETED · sponsor: **Chinese University of Hong Kong** · enrollment: 46 (actual)

## Conditions studied

- Inoperable HCC

## Interventions

- **DRUG:** Torisel

## Key facts

- **NCT ID:** NCT01251458
- **Lead sponsor:** Chinese University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2016-01
- **Final completion:** 2016-01
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2016-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01251458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01251458, "Hepatocellular Carcinoma (HCC)_Torisel_". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01251458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*